date:Dec 10, 2012
eans Evolva will now exploit the Pomecin family of antifungals in collaboration with partners, with only limited further investment by Evolva in the Pomecins beyond their current stage. A number of early-stage discussions are in progress. In addition and as previously announced, the further development of EV-077 (Phase II compound for diabetic complications) and EV-035 (pre-clinical antibiotic) will be via means of partnering or a spin out of these programmes. We expect such activities to comple